- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05135286
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
April 22, 2024 updated by: Visus Therapeutics
Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia
Study Type
Interventional
Enrollment (Estimated)
450
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: David Le
- Phone Number: (800) 281-4536
- Email: david.le@visustx.com
Study Locations
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- M. Farooqi
- Phone Number: 480-999-5458
-
Phoenix, Arizona, United States, 85032
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- A. Buschman
- Phone Number: 480-999-5458
-
Sun City, Arizona, United States, 85351
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- A. Buschman
- Phone Number: 480-999-5458
-
-
California
-
Glendale, California, United States, 91204
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- O. Karram
- Phone Number: 818-246-2560
-
Inglewood, California, United States, 90301
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- C. Caballero-Marin
- Phone Number: 310-641-4673
-
Irvine, California, United States, 92604
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- L. Zavalza
- Phone Number: 949-733-2022
-
Mission Hills, California, United States, 91345
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- K. Taylor
- Phone Number: 661-609-2475
-
Newport Beach, California, United States, 92663
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- R. Castillo
- Phone Number: 949-427-6099
-
Newport Beach, California, United States, 92663
- Active, not recruiting
- Visus Therapeutics Investigative Site
-
Pasadena, California, United States, 91107
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- S. Wade
- Phone Number: 626-793-4168
-
Santa Barbara, California, United States, 93105
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- K. Rosenbusch
- Phone Number: 480-999-5458
-
-
Colorado
-
Littleton, Colorado, United States, 80120
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- Sh. Patel
- Phone Number: 720-709-7533
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- A. Smit
- Phone Number: 203-791-2020
-
-
Florida
-
Crystal River, Florida, United States, 34429
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- N. Smith
- Phone Number: 352-563-1865
-
Delray Beach, Florida, United States, 33484
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- Y. King
- Phone Number: 561-315-5219
-
Fort Lauderdale, Florida, United States, 33309
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- V. Jean-Baptiste
- Phone Number: 954-597-6445
-
Jacksonville, Florida, United States, 32256
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- J. Montgomery
- Phone Number: 904-296-0098
-
Largo, Florida, United States, 33770
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- R. Bondurant
- Phone Number: 727-450-4668
-
Mount Dora, Florida, United States, 32757
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- N. Woodall
- Phone Number: 352-989-0932
-
-
Illinois
-
Lake Villa, Illinois, United States, 60046
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- A. Wojtysiak
- Phone Number: 847-445-5491
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- M. Price
- Phone Number: 317-844-5530
-
-
Kentucky
-
Louisville, Kentucky, United States, 40206
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- J. Powell-Sutton
- Phone Number: 502-589-1500
-
-
Minnesota
-
Bloomington, Minnesota, United States, 55420
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- N. Jacobs
- Phone Number: 612-770-6808
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- M. Hefter
- Phone Number: 816-531-9100
-
Saint Louis, Missouri, United States, 63128
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- K. Tincknell
- Phone Number: 314-842-2020
-
-
Nevada
-
Henderson, Nevada, United States, 89502
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- P. Bouddhabandith
- Phone Number: 480-999-5458
-
-
New York
-
Poughkeepsie, New York, United States, 12603
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- C. Sportiello
- Phone Number: 845-454-1025
-
-
North Carolina
-
Garner, North Carolina, United States, 27529
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- J. Newsome
- Phone Number: 252-904-5415
-
-
North Dakota
-
W. Fargo, North Dakota, United States, 58078
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- A. Saville
- Phone Number: 701-809-9905
-
-
Ohio
-
Powell, Ohio, United States, 43065
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- J. Smith
- Phone Number: 614-793-0700
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- J. Rees
- Phone Number: 503-413-8202
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, United States, 16066
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- N. Hindman
- Phone Number: 724-772-3000
-
Wilkes-Barre, Pennsylvania, United States, 18702
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- B. Michalek
- Phone Number: 570-270-5281
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57108
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- K. Dunne
- Phone Number: 605-361-3937
-
-
Tennessee
-
Maryville, Tennessee, United States, 37803
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- K. Rivera
- Phone Number: 865-671-1234
-
Memphis, Tennessee, United States, 38119
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- D. Ashe
- Phone Number: 901-761-4620
-
Smyrna, Tennessee, United States, 37167
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- M. Medlin
- Phone Number: 615-502-2871
-
-
Texas
-
Hurst, Texas, United States, 76054
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- B. Bott
- Phone Number: 817-540-6060
-
Lakeway, Texas, United States, 78738
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- S. Boldt
- Phone Number: 512-721-8352
-
San Antonio, Texas, United States, 78229
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- C. Hazen
- Phone Number: 210-424-2584
-
-
Utah
-
Draper, Utah, United States, 84020
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- M. Avila, MD
- Phone Number: 801-988-7346
-
-
Virginia
-
Falls Church, Virginia, United States, 22046
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- K. Ng
- Phone Number: 202-239-0777
-
Lynchburg, Virginia, United States, 24502
- Recruiting
- Visus Therapeutics Investigative Site
-
Contact:
- C. Torrence
- Phone Number: 434-947-3984
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male or female in good general health
- Must have presbyopia
Exclusion Criteria:
- History of allergic reaction to the study drug or any of its components
- Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BRIMOCHOL™ PF
A single drop in each eye at a visit.
|
A single drop in each eye at a visit.
Other Names:
|
Active Comparator: Carbachol PF
A single drop in each eye at a visit.
|
A single drop in each eye at a visit.
Other Names:
|
Placebo Comparator: Vehicle
A single drop in each eye at a visit.
|
A single drop in each eye at a visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in near VA
Time Frame: Baseline Day 1
|
Percentage of subjects with 3-line improvement in near VA without the loss of at least 1 line in distance VA
|
Baseline Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2022
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
November 4, 2021
First Submitted That Met QC Criteria
November 19, 2021
First Posted (Actual)
November 26, 2021
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Refractive Errors
- Presbyopia
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Protective Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Cholinergic Agonists
- Miotics
- Brimonidine Tartrate
- Carbachol
Other Study ID Numbers
- VT-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
Lee, Steven, M.D.CompletedMyopia, | Hyperopia, | Astigmatism, | Presbyopia, | Eye Strain,
-
Allotex, Inc.RecruitingPresbyopiaCzechia, Ireland, Turkey, United Kingdom
-
Coopervision, Inc.Centre for Ocular Research & Education, CanadaRecruitingPresbyopiaUnited States, Canada
-
Optall VisionRecruiting
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncCompleted
-
Allotex, Inc.TerminatedPresbyopiaBelgium, Ireland, United Kingdom
-
Coopervision, Inc.CORECompletedPresbyopiaUnited States, Canada
Clinical Trials on BRIMOCHOL™ PF
-
Visus TherapeuticsCompleted
-
Suez Canal UniversityCompleted
-
Suez Canal UniversityCompleted
-
Visus TherapeuticsCompleted
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompletedSchizophreniaUnited States
-
University of FloridaCompletedGastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit TimeUnited States
-
PfizerCompleted